SAI PARENTERALS

To

Date: 17th November, 2026

The Manager **BSE Limited** **P. J. Towers, Dalal Street** **Mumbai-400001** **(BSE Scrip Code: 544742)**	**The Manager** **NSE Limited** **Exchange Plaza, Bandra Kurla Complex,** **Bandra (E), Mumbai- 400051.** **(NSE Symbol: SAIPARENT)**

Dear Sir/Madam,

Unit: Sai Parenteral's Limited

Subject: Press Release

Pursuant to Regulation 30(6) read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the Exchanges that the Company has issued a Press Release titled **"Sai Parenterals' Wholly Owned Subsidiary SP Analytics enters an agreement to Acquire Majority Stake in Bion Therapeutics' Prescription Business"**.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Sai Parenteral's Limited

ASHWANI SINGH BISHT

Digitally signed by ASHWANI SINGH BISHT
Date: 2026.11.17 10:06:14 +05'30'

Ashwani Singh Bisht
Company Secretary & Compliance Officer

Encl: As above

Sai Parenterals Limited

Sai Parenterals' Wholly Owned Subsidiary SP Analytics enters an agreement to Acquire Majority Stake in Bion Therapeutics' Prescription Business

Proposed Acquisition adds 16 established brands and around 250 field staff, strengthening the Company's presence in India's prescription market

Hyderabad, 16th November 2026 – Sai Parenterals Limited has signed a definitive agreement, through its wholly owned subsidiary SP Analytics Private Limited, to acquire a majority stake in Bion Therapeutics India Private Limited (Bion), a Hyderabad-based branded formulations prescription business company. Bion will become a step-down subsidiary of Sai Parenterals on completion of the deal, which is expected before the end of this month. The transaction will be an all-cash deal.

Bion Therapeutics, founded in 2005, is a prescription based branded formulation company that builds products, manufactured with accredited contract manufacturing partners. It operates across 12 states, with a strong presence in South, East and Northeast India, in niche therapeutic segments including neuropathy, diabetes supportive care, mitochondrial health, wound care and pain management.

Doctor-led brands are the core of the business. Unlike trade-led generics, Bion's brands are built through direct, specialty-by-specialty engagement with the doctors who treat these conditions. This gives them strong prescriber recall and loyalty that is difficult for new entrants to replicate.

Bion's portfolio comprises 16 branded formulations, of which power brands like Meaxon, MITOQ7, Adgaba, Sunlite and LG Bion, form its core franchise. It had approximately 250 experienced field staff covering around 20,000 doctors backed by an extensive and well-entrenched distribution network of over 17,000 retailers. Those relationships have been built over nearly two decades, supported by specialty-driven engagement and innovative packaging. This team on the ground, with its knowledge of local markets and prescribers, is what makes the franchise unique.

Bion's extensive infrastructure will provide Sai Parenterals with immediate access to a broader market, enhancing its competitive position in the domestic pharmaceutical landscape. With recent acquisition of Sai Prathyak Laboratories, in-house R&D centre with a portfolio of 174 molecules and 285 SKUs, Bion creates value addition and provides a commercial platform for Sai Parenterals with an established field team to take it to the prescription market.

Sai Parenterals' manufacturing capability creates value addition to Bion. Bion's portfolio is today manufactured from contract manufacturers across several locations. Post acquisition, production will move progressively into Sai Parenterals' own facilities, which hold TGA-Australia and WHO-GMP accreditations. This gives the brands assured supply, consistent quality and improved margins, without reliance on contract manufacturers.

Noumed's dossier library widens the portfolio. Selected molecules from Noumed's library of over 511 TGA-approved dossiers can be introduced to Indian doctors under Bion brands, subject

to Indian regulatory approvals, allowing the field force to promote a larger portfolio across its existing doctor coverage. The critical-care injectable facility SAICRITI at Gummadidala, due for completion in August 2027, in turn gives Bion's injectable brands, led by Meaxon, a route into the hospital and critical-care segments.

Bion's existing management team will continue to spearhead the business following the completion of acquisition, retaining the doctor relationships and market knowledge on which the franchise rests. The transaction will be funded through internal accruals, debt and a portion of the general corporate purposes (GCP) allocation of the Company's initial public offering proceeds. Further particulars of the transaction will be disclosed at the appropriate stage.

Commenting on the agreement, Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, said:

"India's branded formulations market rewards two things above all: brands that doctors trust, and a field organisation disciplined enough to sustain that trust over time. Bion has built both over nearly two decades, power brands led by Meaxon and MITO Q7 Plus, a presence across twelve states and a field organisation of two hundred and fifty people engaging with twenty thousand doctors. A franchise of this nature is established over many years, and it comes to us intact, the brands, the relationships and the organisation that sustains them.

This acquisition completes the platform we have been building. Over the past year we have expanded capacity at Unit III, begun construction of the critical-care injectable facility at Gummadidala, consolidated all our research at Sai Prathyak, and strengthened the Noumed platform in Australia and New Zealand. Each of these strengthens what we are able to develop and manufacture. Bion provides the route to take them to the Indian market directly, converting development capability into branded revenue.

The value flows in both directions. Bion's portfolio, presently manufactured by third parties, will transfer to our accredited facilities, improving supply assurance, quality control and margin. In turn, our development pipeline and Noumed's dossier library give Bion's field organisation a materially wider portfolio to take to market. We will disclose the further particulars of the transaction at the appropriate stage."

Mr. Laxman Prasad Shukla, Managing Director, Bion Therapeutics India Private Limited, said:

"Bion's brands have been built on clinical credibility and sustained engagement with the medical community. Our therapeutic focus, neuropathy, diabetes supportive care, mitochondrial health, wound care and pain management has allowed us to establish depth in the segments that matter to us, rather than breadth for its own sake.

Joining the Sai Parenterals Group addresses the constraint we have felt most acutely: access to manufacturing depth and a development pipeline at the scale our market position warrants. Our team will continue to lead the business and its relationships. What changes is the breadth of the portfolio they are able to take to market."

About the Company

Sai Parenterals Limited is an integrated, IP-led pharmaceutical enterprise operating across two complementary verticals, contract development and manufacturing for international customers, and branded generic formulations sold domestically and exported into regulated and semi-regulated markets. The Company's portfolio spans 302 commercial products across nine therapeutic areas, supported by 599 approved registrations and 76 dossiers under development. It manufactures across five facilities in India carrying GMP, WHO-GMP, TGA-Australia and PIC/S accreditations, with a sixth facility in Adelaide, Australia, and is building an EU-GMP and USFDA-standard injectable facility through Saicriti Pharma, with Group R&D at Sai Prathyak Laboratories. Through Noumed Pharmaceuticals in Australia and New Zealand, acquired in November 2025, the Company holds one of Australia's largest private-label OTC portfolios, with 15 exclusive long-term supply agreements covering 491 SKUs and a library of over 511 TGA-approved dossiers. More than 50% of consolidated revenue is contracted under long-term regulated-market agreements. The Company completed its initial public offering in March 2026 and was listed on the BSE and the NSE on April 02, 2026.

Safe Harbor

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact

Company:	Investor Relations (IR)
Sai Parenterals Limited	**Strategic Growth Advisors Pvt. Ltd.**
CIN: U24231TG2001PLC036043	CIN: U74140MH2010PTC204285
Mr. Anil Kumar, CFO ir@saiparenterals.com saiparenterals.com	Ms. Drashti Shah / Mr. Parin Narichania drashti.shah@sgapl.net / parin.n@sgapl.net +91 87672 24443 / +91 99300 25733 www.sgapl.net